Detlev Biniszkiewicz, NextPoint Therapeutics CEO

Scoop: MPM backs a new check­point in­hibitor biotech in $80M raise

An MPM Cap­i­tal-backed biotech based on the dis­cov­ery of a new im­mune check­point in­hibitor has se­cured about $80 mil­lion in fi­nanc­ing, with for­mer ex­ec­u­tives from Sur­face On­col­o­gy, Syn­dax and blue­bird bio at the helm.

Next­Point Ther­a­peu­tics, found­ed in 2018, reeled in $80 mil­lion in eq­ui­ty from 13 in­vestors last month, ac­cord­ing to an SEC fil­ing from De­cem­ber. A spokesper­son for Boston-based Next­Point de­clined to com­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.